Casey Henich, MD
Family Medicine · West Valley City, UTNPI 1003041740
Payments from drug & device makers
Across 191 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$315
- Novo Nordisk$299
- Boehringer Ingelheim$281
- GSK$276
- AbbVie$217
- Merck$211
- plus $1K from 34 others
What the payments were for
- Food & beverage$3,02799%
- Other$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $315 |
| Novo Nordisk | 22 | $299 |
| Boehringer Ingelheim | 14 | $281 |
| GSK | 18 | $276 |
| AbbVie(2 entities) | 13 | $217 |
| Merck | 16 | $211 |
| Pfizer | 12 | $170 |
| Amgen | 9 | $149 |
| Lucid Diagnostics Inc. | 1 | $113 |
| AstraZeneca | 8 | $105 |
| Johnson & Johnson | 6 | $97 |
| Sanofi-aventis U.S. LLC | 6 | $82 |
| Idorsia Pharmaceuticals US Inc | 4 | $78 |
| Gilead | 3 | $55 |
| Edwards Lifesciences | 2 | $42 |
| Dynavax Technologies Corporation | 3 | $42 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Bayer | 2 | $35 |
| Novartis | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $30 |
| Exact Sciences | 2 | $29 |
| Biogen | 1 | $26 |
| Philips North America LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 2 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $22 |
| Viiv Healthcare Company | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Welch Allyn | 1 | $19 |
| Cranial Technologies, Inc | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| Sobi, Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,046 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 32 | $46,849 |
| JardianceEmpagliflozin | 33 | $36,246 |
| JanuviaSitagliptin Phosphate | 18 | $25,117 |
| EliquisApixaban | 24 | $17,550 |
| OzempicSemaglutide | 15 | $16,299 |
| FarxigaDapagliflozin Propanediol | 14 | $14,575 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $13,404 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,698 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,940 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $4,555 |
| Omeprazole | 186 | $4,171 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,702 |
| Gabapentin | 165 | $3,350 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,300 |
| Atorvastatin Calcium | 280 | $2,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $315 | $46,84932 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $281 | $43,94445 claims |
| MerckJanuvia | $211 | $25,11718 claims |
| AstraZenecaFarxiga, Symbicort | $105 | $17,87530 claims |
| PfizerEliquis | $170 | $17,55024 claims |
| Novo NordiskOzempic | $299 | $16,29915 claims |
| GSKArnuity Ellipta | $276 | $3,70214 claims |
| Sanofi-aventis U.S. LLCLantus | $82 | $2,41920 claims |
| AbbVieSynthroid | $217 | $87316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in West Valley City
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.